The omics-based clinical trials market is projected to grow from $34.49 billion in 2026 to $47.78 billion by 2030, with a CAGR of 8.5%. Growth is fueled by rising demand for personalized medicine, advancements in genomics and proteomics, AI-enhanced patient recruitment, and regulatory acceptance of omics endpoints. Key trends include biomarker-driven trial designs, multi-omics patient stratification, and expansion in precision oncology. Regional growth is notable in Asia-Pacific, supported by collaborations and new genomic labs, while North America remains the market leader. Challenges such as tariffs on sequencing tools are encouraging local development and partnerships.
Pfizer remains an undervalued stock that has underperformed the market but increased 2% since the last analysis. It is viewed as a defensive holding that provides income and helps offset risks related to AI in a diversified portfolio. Despite recent ...
Pfizer is currently undervalued, trading at just over 8 times its projected 2026 earnings and offering a 7% dividend yield. Its core business, excluding COVID-related drugs, grew 7% in Q1, while new products, especially from its acquisition of Seagen...
